Thalidomide was initially promoted as a sedative with anti-emetic properties. Later, Thalidomide was shown to have immunomodulatory and anti-inflammatory properties in erythema nodosum leprosum (ENL). Moreover, Thalidomide was found to inhibit fibroblast growth factor (bFGF)-induced formation of new blood vessels. Thalidomide targets the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and promotes the ubiquitination of Ikaros/Aiolos transcription factors by CRL4CRBN.

KEYWORDS: Thalidomide | supplier | TNFα inhibitor | CAS [50-35-1] | TNF-α | CD120 | Inhibitor | Receptors | Multiple myeloma | Leprosy | Erythema nodosum leprosum | Anti-angiogenic cancer